Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Citigroup Analyst Says

Eli Lilly and Company (NYSE:LLY) had its target price increased by equities researchers at Citigroup from $1,600.00 to $1,650.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup‘s price target would suggest a potential upside of 16.56% from the company’s previous close.

Several other equities research analysts have also issued reports on the stock. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Scotiabank lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday. HSBC upped their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a report on Friday. Finally, Argus raised their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,393.07.

Eli Lilly and Company Trading Up 3.1%

Shares of NYSE LLY traded up $41.94 during midday trading on Friday, hitting $1,415.64. The stock had a trading volume of 5,246,094 shares, compared to its average volume of 2,943,344. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1-year low of $834.19 and a 1-year high of $1,449.68. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 47.50, a PEG ratio of 1.73 and a beta of 0.46. The company has a fifty day moving average price of $1,194.34 and a 200 day moving average price of $1,090.89.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.68 by $1.80. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 earnings per share. On average, analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. Company insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. MFG Investments LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $773,000. Third View Private Wealth LLC lifted its position in shares of Eli Lilly and Company by 5.7% during the third quarter. Third View Private Wealth LLC now owns 2,049 shares of the company’s stock worth $2,371,000 after purchasing an additional 111 shares during the last quarter. Provenance Wealth Advisors LLC raised its stake in Eli Lilly and Company by 5,300.0% during the third quarter. Provenance Wealth Advisors LLC now owns 1,350 shares of the company’s stock valued at $1,562,000 after buying an additional 1,325 shares in the last quarter. Ackerman Capital Advisors LLC lifted its holdings in Eli Lilly and Company by 19.7% during the 3rd quarter. Ackerman Capital Advisors LLC now owns 322 shares of the company’s stock worth $373,000 after buying an additional 53 shares during the last quarter. Finally, One Day In July LLC lifted its holdings in Eli Lilly and Company by 1.6% during the 3rd quarter. One Day In July LLC now owns 567 shares of the company’s stock worth $656,000 after buying an additional 9 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.